Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arctic Bioscience AS ( (DE:9TD) ) has provided an announcement.
Arctic Bioscience held its ordinary general meeting on May 26, 2025, where all agenda items were adopted, including a change in the board of directors. The new board includes Harald Nordal as chairman, along with Jan Endre Vartdal, Tore A. F. Tønseth, Marita Holstad, and Olav Sindre Kriken. This change is part of the company’s ongoing efforts to strengthen its leadership and strategic direction in the biotechnology sector.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is working on HRO350, an oral drug candidate for treating mild-to-moderate psoriasis, and sells dietary supplements globally under the brand ROMEGA®.
YTD Price Performance: 78.79%
Average Trading Volume: 97,003
Current Market Cap: NOK87.83M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.